These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18382427)

  • 41. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
    Hu XC; Zhang J; Xu BH; Cai L; Ragaz J; Wang ZH; Wang BY; Teng YE; Tong ZS; Pan YY; Yin YM; Wu CP; Jiang ZF; Wang XJ; Lou GY; Liu DG; Feng JF; Luo JF; Sun K; Gu YJ; Wu J; Shao ZM
    Lancet Oncol; 2015 Apr; 16(4):436-46. PubMed ID: 25795409
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study.
    Sánchez-Rovira P; Antón A; Barnadas A; Velasco A; Lomas M; Rodríguez-Pinilla M; Ramírez JL; Ramírez C; Ríos MJ; Castellá E; García-Andrade C; San Antonio B; Carrasco E; Palacios JL
    Clin Transl Oncol; 2012 Jun; 14(6):430-6. PubMed ID: 22634531
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Gemcitabine and cisplatin therapy in advanced or metastatic urothelial cancer: comparison of side effect with MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin)].
    Ochi T; Ozawa A; Tanji N; Yanagihara Y; Yanagaki T; Miyauchi Y; Ikeda T; Shimamoto K; Toshino A; Sugawara T; Hamada H; Yokoyama M
    Nihon Hinyokika Gakkai Zasshi; 2006 Sep; 97(6):777-81. PubMed ID: 17025209
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
    Grossi F; de Marinis F; Gebbia V; Riccardi F; Caffo O; Gamucci T; Ferraù F; Nardi M; Moscetti L; Boni L; Dondi D; Galligioni E
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):369-75. PubMed ID: 21833588
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.
    Sandler AB; Nemunaitis J; Denham C; von Pawel J; Cormier Y; Gatzemeier U; Mattson K; Manegold C; Palmer MC; Gregor A; Nguyen B; Niyikiza C; Einhorn LH
    J Clin Oncol; 2000 Jan; 18(1):122-30. PubMed ID: 10623702
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer.
    Wang X; Ni Q; Jin M; Li Z; Wu Y; Zhao Y; Feng F
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):404-7. PubMed ID: 12408777
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
    Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
    Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.
    Firouzabadi D; Dehghanian A; Rezvani A; Mahmoudi L; Talei A
    BMC Cancer; 2021 Jan; 21(1):47. PubMed ID: 33430808
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
    Milowsky MI; Nanus DM; Maluf FC; Mironov S; Shi W; Iasonos A; Riches J; Regazzi A; Bajorin DF
    J Clin Oncol; 2009 Sep; 27(25):4062-7. PubMed ID: 19636012
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer.
    He K; Wang X; Guan X; Yu Q; Ma Q; Liu Z; Yu Z
    Anticancer Res; 2017 Oct; 37(10):5647-5653. PubMed ID: 28982882
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
    Martoni A; Marino A; Sperandi F; Giaquinta S; Di Fabio F; Melotti B; Guaraldi M; Palomba G; Preti P; Petralia A; Artioli F; Picece V; Farris A; Mantovani L
    Eur J Cancer; 2005 Jan; 41(1):81-92. PubMed ID: 15617993
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
    Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.
    Barton S; Hawkes EA; Cunningham D; Peckitt C; Chua S; Wotherspoon A; Attygalle A; Horwich A; Potter M; Ethell M; Dearden C; Gleeson M; Chau I
    Eur J Haematol; 2015 Mar; 94(3):219-26. PubMed ID: 25039915
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study.
    Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Pacilio C; Gravina A; Caputi V; Botti G; Comella G
    Ann Oncol; 1997 Oct; 8(10):1045-8. PubMed ID: 9402180
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
    Pectasides D; Xiros N; Papaxoinis G; Aravantinos G; Sykiotis C; Pectasides E; Psyrri A; Koumarianou A; Gaglia A; Gouveris P; Economopoulos T
    Gynecol Oncol; 2008 Jan; 108(1):47-52. PubMed ID: 17915300
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
    Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
    Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines.
    Vici P; Fabi A; Metro G; Sergi D; Giannarelli D; Di Lauro L; Bepler G; Tomao F; Cognetti F; Conti F; Lopez M
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):687-93. PubMed ID: 20512334
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
    Iyer G; Balar AV; Milowsky MI; Bochner BH; Dalbagni G; Donat SM; Herr HW; Huang WC; Taneja SS; Woods M; Ostrovnaya I; Al-Ahmadie H; Arcila ME; Riches JC; Meier A; Bourque C; Shady M; Won H; Rose TL; Kim WY; Kania BE; Boyd ME; Cipolla CK; Regazzi AM; Delbeau D; McCoy AS; Vargas HA; Berger MF; Solit DB; Rosenberg JE; Bajorin DF
    J Clin Oncol; 2018 Jul; 36(19):1949-1956. PubMed ID: 29742009
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
    Kontopodis E; Kotsakis A; Kentepozidis N; Syrigos K; Ziras N; Moutsos M; Filippa G; Mala A; Vamvakas L; Mavroudis D; Georgoulias V; Agelaki S
    Cancer Chemother Pharmacol; 2016 May; 77(5):949-56. PubMed ID: 26994909
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
    Moore MJ; Winquist EW; Murray N; Tannock IF; Huan S; Bennett K; Walsh W; Seymour L
    J Clin Oncol; 1999 Sep; 17(9):2876-81. PubMed ID: 10561365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.